Regional histopathology and prostate MRI positivity: A secondary analysis of the PROMIS trial

Vasilis Stavrinides, Joseph M. Norris, Solon Karapanagiotis, Francesco Giganti, Alistair Grey, Nick Trahearn, Alex Freeman, Aiman Haider, Lina María Carmona Echeverría, Simon R.J. Bott, Louise C. Brown, Nicholas Burns-Cox, Timothy J. Dudderidge, Ahmed El Shater Bosaily, Maneesh Ghei, Alastair Henderson, Richard G. Hindley, Richard S. Kaplan, Robert Oldroyd, Chris ParkerRaj Persad, Derek J. Rosario, Iqbal S. Shergill, Mathias Winkler, Alex Kirkham, Shonit Punwani, Hayley C. Whitaker, Hashim U. Ahmed, Mark Emberton

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: The effects of regional histopathologic changes on prostate MRI scans have not been accurately quantified in men with an elevated prostate-specific antigen (PSA) level and no previous biopsy. Purpose: To assess how Gleason grade, maximum cancer core length (MCCL), inflammation, prostatic intraepithelial neoplasia (PIN), or atypical small acinar proliferation within a Barzell zone affects the odds of MRI visibility. Materials and Methods: In this secondary analysis of the Prostate MRI Imaging Study (PROMIS; May 2012 to November 2015), consecutive participants who underwent multiparametric MRI followed by a combined biopsy, including 5-mm transperineal mapping (TPM), were evaluated. TPM pathologic findings were reported at the whole-prostate level and for each of 20 Barzell zones per prostate. An expert panel blinded to the pathologic findings reviewed MRI scans and declared which Barzell areas spanned Likert score 3 5 lesions. The relationship of Gleason grade and MCCL to zonal MRI outcome (visible vs nonvisible) was assessed using generalized linear mixed-effects models with random intercepts for individual participants. Inflammation, PIN, and atypical small acinar proliferation were similarly assessed in men who had negative TPM results. Results: Overall, 161 men (median age, 62 years [IQR, 11 years]) were evaluated and 3179 Barzell zones were assigned MRI status. Compared with benign areas, the odds of MRI visibility were higher when a zone contained cancer with a Gleason score of 3+4 (odds ratio [OR], 3.1; 95% CI: 1.9, 4.9; P < .001) or Gleason score greater than or equal to 4+3 (OR, 8.7; 95% CI: 4.5, 17.0; P < .001). MCCL also determined visibility (OR, 1.24 per millimeter increase; 95% CI: 1.15, 1.33; P < .001), but odds were lower with each prostate volume doubling (OR, 0.7; 95% CI: 0.5, 0.9). In men who were TPM-negative, the presence of PIN increased the odds of zonal visibility (OR, 3.7; 95% CI: 1.5, 9.1; P = .004). Conclusion: An incremental relationship between cancer burden and prostate MRI visibility was observed. Prostatic intraepithelial neoplasia contributed to false-positive MRI findings.

Original languageEnglish
Article numbere220762
JournalRadiology
Volume307
Issue number1
DOIs
StatePublished - Apr 2023
Externally publishedYes

Fingerprint

Dive into the research topics of 'Regional histopathology and prostate MRI positivity: A secondary analysis of the PROMIS trial'. Together they form a unique fingerprint.

Cite this